<DOC>
	<DOCNO>NCT00525343</DOCNO>
	<brief_summary>The Avonex Fifteen-year Long-term Follow-up Patients Relapsing Multiple Sclerosis : ASSessment Drug Utilization , EaRly TreAtmeNt , Clinical OutcomEs ( ASSURANCE ) , single-time-point evaluation patient conduct 15 year pivotal MSCRG study , evaluate impact IM IFNβ-1a treatment long-term disability Quality Life outcomes patient complete 2 year previous Multiple Sclerosis Collaborative Research Group ( MSCRG ) study .</brief_summary>
	<brief_title>Avonex 15 Year Long Term Follow-up Study</brief_title>
	<detailed_description>The primary objective study determine impact early versus delay initiation treatment long-term physical status patient relapse form MS measure self-reported EDSS . Primary endpoint study follow : 1 . Changes EDSS score baseline original Avonex® pivotal trial 2 . Percentage patient EDSS score less equal 4 3 . Percentage patient EDSS score less equal 6 4 . Percentage patient EDSS score less equal 7 Secondary endpoint : 1 . Percentage patient alive 2 . Percentage patient live independently 3 . SF 36 Quality Life status 4 . Self-reported VAS independence self-care</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>1 . Patients complete least 2 year treatment ( Avonex® placebo ) original Avonex® pivotal trial . 2 . Subjects ( caregiver ) must willing complete multipage questionnaire . 3 . Signed write informed consent form 1 . Unwillingness inability comply requirement protocol . 2 . Any reason , opinion Investigator , subject determine unsuitable enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Avonex pivotal trial</keyword>
	<keyword>Avonex</keyword>
	<keyword>Avonex long term follow-up</keyword>
	<keyword>Avonex outcome</keyword>
</DOC>